© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 3, 173-181,
February 6, 2002
© 2002 Oxford University Press
ARTICLE |
Cisplatin-Based Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Implications of Eastern Cooperative Oncology Group 5592, a Randomized Trial
Affiliations of authors: C. J. Langer, Fox Chase Cancer Center, Philadelphia, PA; J. Manola, P. Bernardo, Dana-Farber Cancer Institute, Boston, MA; J. W. Kugler, Illinois Oncology Research Association, Peoria; P. Bonomi, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL; D. Cella, Northwestern Healthcare and Northwestern University, Evanston, IL; D. H. Johnson, Vanderbilt University, Nashville, TN.
Correspondence to: Corey J. Langer, M.D., Fox Chase Cancer Center, 7701 Burholme Ave., Philadelphia, PA 19111 (e-mail: CJ_Langer{at}fccc.edu).
Background: Older patients, even if fit, are often considered incapable of tolerating platinum-based systemic therapy. We performed a retrospective analysis of Eastern Cooperative Oncology Group (ECOG) 5592, a phase III randomized trial of platinum-based chemotherapy regimens for non-small-cell lung cancer (NSCLC), and compared outcomes in enrollees 70 years of age and older with those in younger patients. Methods: ECOG carried out a randomized phase III trial of cisplatin plus either etoposide or paclitaxel in chemotherapy-naïve NSCLC patients with stages IIIB or IV disease. Toxic effects, response rates, and survival rates were compared between age groups. All P values were two-sided. Results: A total of 574 patients enrolled from August 1993 through December 1994 were evaluable. Eighty-six (15%) were 70 years old or older. Older patients had a higher incidence of cardiovascular (P = .009) and respiratory (P = .04) comorbidities and nonanalgesic medication use (P = .02). Leukopenia (P<.001) and neuropsychiatric toxicity (P = .002) were more common in elderly men than in younger men. Elderly women lost more weight than younger women (P = .006). Other toxic effects were similar in older and younger patients. The proportions with clinical partial or complete response (21.5% versus 23.3%; Fisher's exact test, P = .66), median time to progression (4.37 versus 4.30 months; log-rank test, P = .29), and survival distribution (log-rank test, P = .29; median survival, 9.05 versus 8.53 months; 1-year survival, 38% versus 29%; and 2-year survival, 14% versus 12%) were similar in patients younger than 70 years and 70 years old or older. Baseline quality-of-life and treatment-outcome indices were similar. Equivalent declines over time in functional well-being occurred in both groups. Conclusion: Response rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients, although patients 70 years old or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity. Advanced age alone should not preclude appropriate NSCLC treatment.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Sakakibara, A. Inoue, S. Sugawara, M. Maemondo, T. Ishida, K. Usui, T. Abe, M. Kanbe, H. Watanabe, Y. Saijo, et al. Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer Ann. Onc., October 8, 2009; (2009) mdp401v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Pallis, C. Gridelli, J. P. van Meerbeeck, L. Greillier, U. Wedding, D. Lacombe, J. Welch, C. P. Belani, and M. Aapro EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population Ann. Onc., August 28, 2009; (2009) mdp360v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. H. Gronberg, R. M. Bremnes, O. Flotten, T. Amundsen, P. Fr. Brunsvig, H. H. Hjelde, S. Kaasa, C. von Plessen, F. Stornes, T. Tollali, et al. Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., July 1, 2009; 27(19): 3217 - 3224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Ramalingam and F. R. Khuri The Role of the Taxanes in the Treatment of Older Patients with Advanced Stage Non-Small Cell Lung Cancer Oncologist, April 1, 2009; 14(4): 412 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gridelli, P. Maione, and A. Rossi Chemotherapy and Targeted Therapy for Older Patients with Advanced Non-small Cell Lung Cancer ASCO Educational Book, January 1, 2009; 2009(1): 283 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Berhoune, E. Banu, F. Scotte, P. Prognon, S. Oudard, and B. Bonan Therapeutic Strategy for Treatment of Metastatic Non-Small Cell Lung Cancer Ann. Pharmacother., November 1, 2008; 42(11): 1640 - 1652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Eisen, S. Oudard, C. Szczylik, G. Gravis, H. Heinzer, R. Middleton, F. Cihon, S. Anderson, S. Shah, R. Bukowski, et al. Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial J Natl Cancer Inst, October 15, 2008; 100(20): 1454 - 1463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Crino, F. Cappuzzo, P. Zatloukal, M. Reck, M. Pesek, J. C. Thompson, H. E.R. Ford, F. R. Hirsch, M. Varella-Garcia, S. Ghiorghiu, et al. Gefitinib Versus Vinorelbine in Chemotherapy-Naive Elderly Patients With Advanced Non-Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study J. Clin. Oncol., September 10, 2008; 26(26): 4253 - 4260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fruh, E. Rolland, J.-P. Pignon, L. Seymour, K. Ding, H. Tribodet, T. Winton, T. Le Chevalier, G. V. Scagliotti, J. Y. Douillard, et al. Pooled Analysis of the Effect of Age on Adjuvant Cisplatin-Based Chemotherapy for Completely Resected Non-Small-Cell Lung Cancer J. Clin. Oncol., July 20, 2008; 26(21): 3573 - 3581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Wheatley-Price, K. Ding, L. Seymour, G. M. Clark, and F. A. Shepherd Erlotinib for Advanced Non-Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21 J. Clin. Oncol., May 10, 2008; 26(14): 2350 - 2357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Ramalingam, S. E. Dahlberg, R. Gray, C. J. Langer, C. P. Belani, J. R. Brahmer, A. B. Sandler, J. H. Schiller, and D. H. Johnson Meaningful Subset Analyses Contribute to Optimal Patient Care J. Clin. Oncol., April 20, 2008; 26(12): 2064 - 2065. [Full Text] [PDF]
|
|
|
|
|
|
N. A. Rizvi, G. J. Riely, C. G. Azzoli, V. A. Miller, K. K. Ng, J. Fiore, G. Chia, M. Brower, R. Heelan, M. J. Hawkins, et al. Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel As Initial Chemotherapy in Patients With Stage IV Non-Small-Cell Lung Cancer J. Clin. Oncol., February 1, 2008; 26(4): 639 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Asmis, K. Ding, L. Seymour, F. A. Shepherd, N. B. Leighl, T. L. Winton, M. Whitehead, J. N. Spaans, B. C. Graham, and G. D. Goss Age and Comorbidity As Independent Prognostic Factors in the Treatment of Non-Small-Cell Lung Cancer: A Review of National Cancer Institute of Canada Clinical Trials Group Trials J. Clin. Oncol., January 1, 2008; 26(1): 54 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Ramalingam, S. E. Dahlberg, C. J. Langer, R. Gray, C. P. Belani, J. R. Brahmer, A. B. Sandler, J. H. Schiller, and D. H. Johnson Outcomes for Elderly, Advanced-Stage Non Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599 J. Clin. Oncol., January 1, 2008; 26(1): 60 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Balducci, H. Al-Halawani, V. Charu, J. Tam, S. Shahin, L. Dreiling, and W. B. Ershler Elderly Cancer Patients Receiving Chemotherapy Benefit from First-Cycle Pegfilgrastim Oncologist, December 1, 2007; 12(12): 1416 - 1424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gridelli, P. Maione, A. Illiano, F. V. Piantedosi, A. Favaretto, A. Bearz, S. F. Robbiati, V. Filipazzi, V. Lorusso, F. Carrozza, et al. Cisplatin Plus Gemcitabine or Vinorelbine for Elderly Patients With Advanced Non Small-Cell Lung Cancer: The MILES-2P Studies J. Clin. Oncol., October 10, 2007; 25(29): 4663 - 4669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Socinski, R. Crowell, T. E. Hensing, C. J. Langer, R. Lilenbaum, A. B. Sandler, and D. Morris Treatment of Non-small Cell Lung Cancer, Stage IV: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 277S - 289S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Temel, V. A. Jackson, J. A. Billings, C. Dahlin, S. D. Block, M. K. Buss, P. Ostler, P. Fidias, A. Muzikansky, J. A. Greer, et al. Phase II Study: Integrated Palliative Care in Newly Diagnosed Advanced Non-Small-Cell Lung Cancer Patients J. Clin. Oncol., June 10, 2007; 25(17): 2377 - 2382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Lichtman, H. Wildiers, E. Chatelut, C. Steer, D. Budman, V. A. Morrison, B. Tranchand, I. Shapira, and M. Aapro International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of Chemotherapy in Older Patients--An Analysis of the Medical Literature J. Clin. Oncol., May 10, 2007; 25(14): 1832 - 1843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Muss, L. Biganzoli, D. J. Sargent, and M. Aapro Adjuvant Therapy in the Elderly: Making the Right Decision J. Clin. Oncol., May 10, 2007; 25(14): 1870 - 1875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gridelli, C. Langer, P. Maione, A. Rossi, and S. E. Schild Lung Cancer in the Elderly J. Clin. Oncol., May 10, 2007; 25(14): 1898 - 1907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pepe, B. Hasan, T. L. Winton, L. Seymour, B. Graham, R. B. Livingston, D. H. Johnson, J. R. Rigas, K. Ding, and F. A. Shepherd Adjuvant Vinorelbine and Cisplatin in Elderly Patients: National Cancer Institute of Canada and Intergroup Study JBR.10 J. Clin. Oncol., April 20, 2007; 25(12): 1553 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Jackman, B. Y. Yeap, N. I. Lindeman, P. Fidias, M. S. Rabin, J. Temel, A. T. Skarin, M. Meyerson, A. J. Holmes, A. M. Borras, et al. Phase II Clinical Trial of Chemotherapy-Naive Patients >= 70 Years of Age Treated With Erlotinib for Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., March 1, 2007; 25(7): 760 - 766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Langer Mind Your Elders: Therapeutic Implications of Epidermal Growth Factor Receptor Inhibition in Older Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., March 1, 2007; 25(7): 751 - 753. [Full Text] [PDF]
|
|
|
|
|
|
G. J. Weiss, C. Langer, R. Rosell, N. Hanna, F. Shepherd, L. H. Einhorn, B. Nguyen, S. Paul, P. McAndrews, P. A. Bunn Jr, et al. Elderly Patients Benefit From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized Phase III Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., September 20, 2006; 24(27): 4405 - 4411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kudoh, K. Takeda, K. Nakagawa, M. Takada, N. Katakami, K. Matsui, T. Shinkai, T. Sawa, I. Goto, H. Semba, et al. Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904) J. Clin. Oncol., August 1, 2006; 24(22): 3657 - 3663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Auperin, C. Le Pechoux, J. P. Pignon, C. Koning, B. Jeremic, G. Clamon, L. Einhorn, D. Ball, M. G. Trovo, H. J. M. Groen, et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients Ann. Onc., March 1, 2006; 17(3): 473 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jatoi, S. Hillman, P. Stella, E. Green, A. Adjei, S. Nair, E. Perez, B. Amin, S. E. Schild, R. Castillo, et al. Should Elderly Non-Small-Cell Lung Cancer Patients Be Offered Elderly-Specific Trials? Results of a Pooled Analysis From the North Central Cancer Treatment Group J. Clin. Oncol., December 20, 2005; 23(36): 9113 - 9119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Matsuoka, M. Okada, T. Sakamoto, and N. Tsubota Reply to Altundag et al. Eur. J. Cardiothorac. Surg., December 1, 2005; 28(6): 912 - 912. [Full Text] [PDF]
|
|
|
|
|
|
T. Wasil and S. M. Lichtman Clinical Pharmacology Issues Relevant to the Dosing and Toxicity of Chemotherapy Drugs in the Elderly Oncologist, September 1, 2005; 10(8): 602 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gridelli and F. A. Shepherd Chemotherapy for Elderly Patients With Non-Small Cell Lung Cancer: A Review of the Evidence Chest, August 1, 2005; 128(2): 947 - 957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-M. Chen, R.-P. Perng, J.-F. Shih, C.-M. Tsai, and J. Whang-Peng Chemotherapy for Non-small Cell Lung Cancer in Elderly Patients Chest, July 1, 2005; 128(1): 132 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rossi, P. Maione, G. Colantuoni, C. Guerriero, C. Ferrara, F. Del Gaizo, D. Nicolella, and C. Gridelli Treatment of Small Cell Lung Cancer in the Elderly Oncologist, June 1, 2005; 10(6): 399 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gridelli, M. Aapro, A. Ardizzoni, L. Balducci, F. De Marinis, K. Kelly, T. Le Chevalier, C. Manegold, F. Perrone, R. Rosell, et al. Treatment of Advanced Non-Small-Cell Lung Cancer in the Elderly: Results of an International Expert Panel J. Clin. Oncol., May 1, 2005; 23(13): 3125 - 3137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Okamoto, E. Moriyama, S. Fujii, H. Kishi, M. Nomura, E. Goto, C. Kiyofuji, F. Imamura, T. Mori, and M. Matsumoto Phase II Study of Carboplatin-Paclitaxel Combination Chemotherapy in Elderly Patients with Advanced Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., April 1, 2005; 35(4): 188 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Atagi, M. Kawahara, T. Tamura, K. Noda, K. Watanabe, A. Yokoyama, T. Sugiura, H. Senba, S. Ishikura, H. Ikeda, et al. Standard Thoracic Radiotherapy With or Without Concurrent Daily Low-dose Carboplatin in Elderly Patients with Locally Advanced Non-small Cell Lung Cancer: a Phase III Trial of the Japan Clinical Oncology Group (JCOG9812) Jpn. J. Clin. Oncol., April 1, 2005; 35(4): 195 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hoang, R. Xu, J. H. Schiller, P. Bonomi, and D. H. Johnson Clinical Model to Predict Survival in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Treated With Third-Generation Chemotherapy Regimens Based on Eastern Cooperative Oncology Group Data J. Clin. Oncol., January 1, 2005; 23(1): 175 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Lilenbaum, J. E. Herndon II, M. A. List, C. Desch, D. M. Watson, A. A. Miller, S. L. Graziano, M. C. Perry, W. Saville, P. Chahinian, et al. Single-Agent Versus Combination Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The Cancer and Leukemia Group B (study 9730) J. Clin. Oncol., January 1, 2005; 23(1): 190 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Ramsey, N. Howlader, R. D. Etzioni, and B. Donato Chemotherapy Use, Outcomes, and Costs for Older Persons With Advanced Non-Small-Cell Lung Cancer: Evidence From Surveillance, Epidemiology and End Results-Medicare J. Clin. Oncol., December 15, 2004; 22(24): 4971 - 4978. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Jennens, R. de Boer, L. Irving, D. L. Ball, and M. A. Rosenthal Differences of Opinion: A Survey of Knowledge and Bias Among Clinicians Regarding the Role of Chemotherapy in Metastatic Non-small Cell Lung Cancer Chest, December 1, 2004; 126(6): 1985 - 1993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Makrantonakis, E. Galani, and P. G. Harper Non-Small Cell Lung Cancer in the Elderly Oncologist, September 1, 2004; 9(5): 556 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. L. Read, R. M. Tierney, N. C. Page, I. Costas, R. Govindan, E. L.J. Spitznagel, and J. F. Piccirillo Differential Prognostic Impact of Comorbidity J. Clin. Oncol., August 1, 2004; 22(15): 3099 - 3103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Minami, Y. Ohe, S. Niho, K. Goto, H. Ohmatsu, K. Kubota, R. Kakinuma, Y. Nishiwaki, H. Nokihara, I. Sekine, et al. Comparison of Pharmacokinetics and Pharmacodynamics of Docetaxel and Cisplatin in Elderly and Non-Elderly Patients: Why Is Toxicity Increased in Elderly Patients? J. Clin. Oncol., July 15, 2004; 22(14): 2901 - 2908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Socinski, C. Zhang, J. E. Herndon II, R. O. Dillman, G. Clamon, E. Vokes, W. Akerley, J. Crawford, M. C. Perry, S. L. Seagren, et al. Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity Ann. Onc., July 1, 2004; 15(7): 1033 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003 J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353. [Full Text] [PDF]
|
|
|
|
|
|
A. Argiris, Y. Li, B. A. Murphy, C. J. Langer, and A. A. Forastiere Outcome of Elderly Patients With Recurrent or Metastatic Head and Neck Cancer Treated With Cisplatin-Based Chemotherapy J. Clin. Oncol., January 15, 2004; 22(2): 262 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ohe, S. Niho, R. Kakinuma, K. Kubota, H. Ohmatsu, K. Goto, H. Nokihara, H. Kunitoh, N. Saijo, H. Aono, et al. A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients Ann. Onc., January 1, 2004; 15(1): 45 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Balducci Lung Cancer in the Elderly: So Many Patients, So Little Time! CA Cancer J Clin, November 1, 2003; 53(6): 322 - 324. [Full Text] [PDF]
|
|
|
|
|
|
A. Hurria and M. G. Kris Management of Lung Cancer in Older Adults CA Cancer J Clin, November 1, 2003; 53(6): 325 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.T. Hennessy, E.O. Hanrahan, and O.S. Breathnach Chemotherapy Options for the Elderly Patient with Advanced Non-Small Cell Lung Cancer Oncologist, June 1, 2003; 8(3): 270 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Bunn Jr. and R. Lilenbaum Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer J Natl Cancer Inst, March 5, 2003; 95(5): 341 - 343. [Full Text] [PDF]
|
|
|
|
|
|
C. Gridelli, F. Perrone, C. Gallo, S. Cigolari, A. Rossi, F. Piantedosi, S. Barbera, F. Ferrau, E. Piazza, F. Rosetti, et al. Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial J Natl Cancer Inst, March 5, 2003; 95(5): 362 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Bunn Jr Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Who, What, When, Why? J. Clin. Oncol., September 15, 2002; 20(90001): 23s - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Bunn Jr Treatment of Advanced Non-Small-Cell Lung Cancer With Two-Drug Combinations J. Clin. Oncol., September 1, 2002; 20(17): 3565 - 3567. [Full Text] [PDF]
|
|
|
|
|
|
F. Perrone, C. Gallo, and C. Gridelli Re: Cisplatin-Based Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Implications of Eastern Cooperative Oncology Group 5592, a Randomized Trial J Natl Cancer Inst, July 3, 2002; 94(13): 1029 - 1030. [Full Text] [PDF]
|
|
|
|
|
|
C. J. Langer and D. H. Johnson RESPONSE: Re: Cisplatin-Based Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Implications of Eastern Cooperative Oncology Group 5592, a Randomized Trial J Natl Cancer Inst, July 3, 2002; 94(13): 1030 - 1031. [Full Text] [PDF]
|
|